Skip to search formSkip to main contentSkip to account menu
  • Publications
  • Influence
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
TLDR
The addition of enalapril to conventional therapy significantly reduced mortality and hospitalizations for heart failure in patients with chronic congestive heart failure and reduced ejection fractions.
View on PubMed
Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.
View on PubMed
Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.
TLDR
Measurements of Hemodynamics, plasma norepinephrine, and plasma renin activity in patients with moderate to severe congestive heart failure suggest that a single resting venous blood sample showing the plasma norenphrine concentration provides a better guide to prognosis than other commonly measured indexes of cardiac performance.
View on PubMed
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
TLDR
Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy, and raises concern about the potential safety of this specific combination.
View on PubMed
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
TLDR
Carvedilol reduces the risk or death as well as the risk of hospitalization for cardiovascular causes in patients with heart failure who are receiving treatment with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor.
View on PubMed
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.
TLDR
The angiotensin-converting--enzyme inhibitor enalapril significantly reduced the incidence of heart failure and the rate of related hospitalizations, as compared with the rates in the group given placebo, among patients with asymptomatic left ventricular dysfunction.
View on PubMed
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
TLDR
The different effects of the two regimens (enalapril and hydralazine-isosorbide dinitrate) on mortality and physiologic end points suggest that the profile of effects might be enhanced if the regimens were used in combination.
View on PubMed
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
TLDR
The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy for heart failure including neurohormonal blockers is efficacious and increases survival among black patients with advanced heart failure.
View on PubMed
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan.…
View on PubMed
Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License